Ash 2022 – Syndax and Kura face off
Duelling datasets on the companies’ rival menin inhibitors show each to have weaknesses and strengths.
Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Ash 2021 preview – small increases and big falls
The early movers could point to a disappointing meeting.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
